Recap of NanoViricides, Inc. CEO Dr. Eugene Seymour Clear Channel Business Talk Radio Interview
December 23 2013 - 12:17PM
Marketwired
Recap of NanoViricides, Inc. CEO Dr. Eugene Seymour Clear Channel
Business Talk Radio Interview
Host Michael Yorba of The Traders Network Welcomed Seymour on
Clear Channel's DFW 1190AM
WEST HAVEN, CT--(Marketwired - Dec 23, 2013) - NanoViricides,
Inc. (NYSEMKT: NNVC) is a development stage company that is
creating special purpose nanomaterials to destroy viruses in and on
the body. The Company today announced that Michael Yorba of Clear
Channel's Business Talk Radio Show, The Traders Network,
interviewed CEO Dr. Eugene Seymour live on December 19, 2013.
In this very informative one on one interview, Dr Seymour was
asked about their platform technology to rapidly create anti-viral
drugs and how it related to HIV/AIDS and other viral
diseases. He explained the construction and function of their
line-up of drugs all work on the same basic principle. A
nanomicelle that is a 20 nanometer polymeric-based structure
attached to a "mimic" of the receptor protein that sits on the host
cell that is then used to lure the virus to the cell. For example;
Influenza is a virus that causes the illness known at "flu." If you
can at least control, or better yet, destroy the virus in the
bloodstream, you can reverse the symptoms of the illness, allowing
the patient to recover quickly.
He went on to explain that viruses only grow in cells and thus
in order for the virus to reproduce, it must attach to and enter
their unique host cell. In an effort to "fool" the virus into
attaching to our nanoviricide, we place a "mimic" of the receptor
protein found on the surface of the host cell of that particular
virus on our nanomicelle, creating the nanoviricide. The
nanoviricide then opens up, encapsulates and then destroys the
virus. Once you understand this, you understand how all our drugs
work.
Yorba asked, "How is your drug administered?"
For influenza, we plan an intravenous route of administration
for seriously or critically ill hospitalized patients. For
outpatients, we're planning to use a single dose oral liquid. For
herpes of the eye, eye drops and for genital herpes, we plan to use
an ointment. For HIV/AIDS, initially an intravenous loading
dose.
At this point Dr. Seymour reminded listeners that they still
need to do human trials, and would have much more information after
those trials have been completed.
NanoViricides, Inc.'s achievements this past year was, receiving
orphan drug designation from the European Union and the US FDA for
DengueCide, their drug for Dengue Hemorrhagic Fever, and Dengue.
Also starting construction of their high tech, state of the art
nano-medicine anti-viral drug manufacturing plant, the only one in
the US and possibly the entire world. Next year's plans include:
finishing the plant, completing toxicology studies and submitting
paperwork to FDA, while awaiting for permission to start human
trials.
Listen to the entire live archive Clear Channel Interview,
detail below.
Archive Interview Link:
http://www.yorbamedia.com/images/stories/audio/TN121913SEG1.mp3
Network: Clear Channel Station: DFW 1190AM Host: Michael
Yorba
Michael Yorba host of Clear Channel's The Traders Network Show
later stated, "What NanoViricides is doing is simply a game
changer! We look forward to having Dr. Seymour back for a part-2
interview in 2014. We are expecting big things from this
company."
About Clear Channel Clear
Channel Media and Entertainment's more than 840 radio stations
offer programming nationwide. Individual station brands connect
with diverse audiences in local markets across the country.
DFW1190AM.com Dallas-Ft. Worth, TX (www.clearchannel.com).
About Michael Yorba Michael
Yorba -- featured host of Clear Channels DFW 1190AM in
Dallas-Ft.Worth. For the past six years he has been integrally
involved with the media industry in various capacities including
building an IPTV Network, developing, producing and hosting a daily
one hour talk show called Commodity Classics and then later The
Traders Network, defined as an audience empowered interactive
financial program that has been broadcast live on internet
television and radio. His focus has been on derivative portfolio
analysis for individual and corporate clients through the use of
futures and futures options, managed funds, and Forex.
www.yorbamedia.com.
About NanoViricides
NanoViricides, Inc.
(www.nanoviricides.com) is a development stage company that is
creating special purpose nanomaterials for viral therapy. The
Company's novel nanoviricide® class of drug candidates are designed
to specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains
forward-looking statements that reflect the Company's current
expectation regarding future events. Actual events could differ
materially and substantially from those projected herein and depend
on a number of factors. Certain statements in this release, and
other written or oral statements made by NanoViricides, Inc. are
"forward-looking statements" within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. You should not place undue reliance on
forward-looking statements since they involve known and unknown
risks, uncertainties and other factors that are, in some cases,
beyond the Company's control and which could, and likely will,
materially affect actual results, levels of activity, performance
or achievements. The Company assumes no obligation to publicly
update or revise these forward-looking statements for any reason,
or to update the reasons actual results could differ materially
from those anticipated in these forward-looking statements, even if
new information becomes available in the future. Important factors
that could cause actual results to differ materially from the
company's expectations include, but are not limited to, those
factors that are disclosed under the heading "Risk Factors" and
elsewhere in documents filed by the company from time to time with
the United States Securities and Exchange Commission and other
regulatory authorities. Although it is not possible to predict or
identify all such factors, they may include the following:
demonstration and proof of principle in pre-clinical trials that a
nanoviricide is safe and effective; successful development of our
product candidates; our ability to seek and obtain regulatory
approvals, including with respect to the indications we are
seeking; the successful commercialization of our product
candidates; and market acceptance of our products.
A
www.1800PublicRelations.com PR Event
Contacts: Company NanoViricides, Inc. Amanda Schuon
310-550-7200 info@nanoviricides.com Press | Media Matthew Bird
President MUNCmedia Public Relations (917) 409-8211
matt.bird@muncmedia.com www.muncmedia.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Mar 2024 to Apr 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Apr 2023 to Apr 2024